<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548742</url>
  </required_header>
  <id_info>
    <org_study_id>SPLE-012-11S</org_study_id>
    <secondary_id>CX-11-012</secondary_id>
    <nct_id>NCT01548742</nct_id>
  </id_info>
  <brief_title>Meditation Interventions for Treatment of PTSD in Veterans</brief_title>
  <acronym>VMP</acronym>
  <official_title>Meditation Interventions for Treatment of PTSD in Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder which results in
      serious impairments in interpersonal, occupational and social functioning. Effective
      treatments are available for PTSD but they do not work for everyone. Alternative treatments
      are needed to help those veterans not helped by currently available treatments. Mindfulness
      Based Stress Reduction (MBSR) is a group based treatment focused on mindfulness meditation.
      MBSR has been found to be effective in helping people with problems with pain and anxiety.
      MBSR has not yet been studied in veterans with PTSD. The proposed study will compare MBSR
      with a standard psychotherapy treatment in veterans with PTSD. This research is relevant to
      Veterans' health because of the need to develop alternative treatments for veterans with PTSD
      who have not responded to currently available treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder associated with
      high rates of chronicity, poor quality of life, and severe impairments in interpersonal,
      occupational, and social functioning. While evidence-based psychotherapies for treatment of
      PTSD have been developed and disseminated within the VA system, no treatment has shown
      universal effectiveness and there have been great concerns about attenuated treatment
      response and elevated treatment drop out in veteran populations. The evaluation of
      alternative treatment modalities for veterans with PTSD is therefore an important priority.
      The Minneapolis VA Health Care System (MVAHCS) has taught Mindfulness Based Stress Reduction
      (MBSR), a group-based intervention focused on mindfulness meditation, to veteran clinical
      populations since 2001, and pilot data from veterans diagnosed with PTSD is promising.
      Despite support for the application of MBSR to other mental health and physical problems,
      MBSR has not been systematically evaluated as a treatment for PTSD. Moreover, the existing
      literature on MBSR is limited by methodological weaknesses. If shown to be efficacious
      through scientifically sound trials, MSBR may offer an effective, acceptable, and tolerable
      intervention for veterans suffering PTSD who are unable to engage in or complete traditional
      exposure-based therapies. The primary goal of this proposal is to conduct a methodologically
      rigorous randomized controlled trial (RCT) of MBSR in treating PTSD among veterans, examining
      both symptom outcomes and subsequent health services utilization. Given our compelling pilot
      data, we propose initial steps to evaluate putative mechanisms of change (self-report and
      electrophysiology markers, i.e., EEG) through which MBSR may relate to PTSD symptom
      improvements, and to examine the acceptability of MBSR to the veteran population.

      The MVAHCS and the assembled team combines expertise in PTSD treatment and research, clinical
      trials, and neuroscience, with clinical expertise in MBSR and compelling pilot data to
      support the feasibility and scope of the current project. The efficacy of MBSR will be
      examined relative to present-centered group therapy (PCGT), a non-specific therapeutic
      comparison group. Veterans diagnosed with PTSD will be randomized to MBSR or PCGT for 9
      weeks. Each intervention will be delivered in group format following manualization by trained
      clinicians receiving expert supervision. Treatment integrity will be independently monitored.
      Assessment of clinical outcomes post-treatment and 2 months follow-up will be independently
      evaluated. Putative mechanisms of mindfulness meditation will be assessed using self-report
      and electrophysiology markers. We have the following aims:

      Primary Aim 1: To evaluate the efficacy of MBSR as a treatment for PTSD in veterans compared
      to PCGT over 9-weeks of treatment and 2-month follow-up.

      Secondary Aim 1: To identify potential treatment-based predictors of PTSD outcomes.

      Secondary Aim 2: To identify differences in subsequent VA health services utilization among
      veterans across treatment conditions.

      Exploratory Aims:

        1. To evaluate rates of drop-out, compliance, and consumer satisfaction with MBSR.

        2. To evaluate acceptability and outcomes of treatment with veterans with mild traumatic
           brain injuries.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PTSD Symptoms on the PTSD Checklist (PCL) at Baseline, During Treatment, After Treatment and at 2-Month Follow-up</measure>
    <time_frame>Baseline, Weeks 3, 6, 9 and 17</time_frame>
    <description>The PCL is a valid and reliable measure of PTSD symptoms. Score range from 17-85; higher scores indicate more severe symptoms. The minimal clinically important difference for self-reported PTSD symptom severity is a reduction of 10 or more points on the PCL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTSD Symptom Severity on the Clinician Administered PTSD Scale (CAPS) at Baseline, After Treatment, and at 2-Month Follow-up</measure>
    <time_frame>Baseline, Weeks 9 and 17</time_frame>
    <description>The CAPS is a valid and reliable measure of PTSD symptom severity. Score range from 0-136; higher scores indicate more severe symptoms. The minimal clinically important difference for self-reported PTSD symptom severity is a reduction of 10 or more points on the CAPS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Symptom Severity on the Patient Health Questionnaire-9 (PHQ-9) at Baseline, After Treatment, and at 2-Month Follow-up</measure>
    <time_frame>Baseline, Weeks 9 and 17</time_frame>
    <description>The PHQ-9 is a valid and reliable measure of depression symptom severity. Score range from 0-27; higher scores indicate more severe symptoms. The minimal clinically important difference for self-reported PTSD symptom severity is a reduction of 5 or more points on the PHQ-9.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinically Significant Improvement in Self-reported PTSD Symptoms as Measured by the PCL</measure>
    <time_frame>Weeks 9 and 17</time_frame>
    <description>% of participants with clinically significant improvement in self-reported PTSD symptoms defined as a reduction of 10 points or more on the PCL.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically Significant Improvement in Clinician Administered PTSD Scale (CAPS)</measure>
    <time_frame>Weeks 9 and 17</time_frame>
    <description>% of participants with clinically significant improvement in interviewer-rated PTSD symptom severity defined as a reduction of 10 points or more on the CAPS.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>Arm 1: Mindfulness-Based Stress Reduction (MBSR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mindfulness-Based Stress Reduction (MBSR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Present-Centered Group Therapy (PCGT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Present-Centered Group Therapy (PCGT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindfulness-Based Stress Reduction (MBSR)</intervention_name>
    <description>Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.</description>
    <arm_group_label>Arm 1: Mindfulness-Based Stress Reduction (MBSR)</arm_group_label>
    <other_name>MBSR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Present-Centered Group Therapy (PCGT)</intervention_name>
    <description>Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.</description>
    <arm_group_label>Arm 2: Present-Centered Group Therapy (PCGT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female veterans who are 18 years or older.

          -  Must meet current DSM-IV criteria for PTSD based on the Clinician Administered PTSD
             Scale (CAPS) or have a PTSD Checklist (PCL) score between 40 and 60.

          -  If taking psychoactive medications, must be on a stable regime for 8 weeks or more.

        Exclusion Criteria:

          -  Current suicidal or homicidal ideation with intent and/or plan that, in the judgment
             of the investigator, should be the focus of treatment.

          -  Current substance dependence (not in sustained remission), current or recent (within
             past 6 months) manic episode, or active psychosis. To be eligible, if veteran has
             current diagnosis of bipolar disorder, there is evidence that illness has been stable
             for at least 6 months on medication. Has unstable or serious medical illness,
             including history of stroke, seizure disorder, or unstable cardiac disease that would
             interfere with participation in treatment.

          -  Severe cognitive impairment or moderate/severe traumatic brain injury.

          -  Unable to comprehend or communicate in English.

          -  Unwilling to accept random assignment or unwilling to refrain from participating in
             other active forms of psychotherapy during 8-week treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelvin Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis VA Health Care System, Minneapolis, MN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <results_first_submitted>September 29, 2015</results_first_submitted>
  <results_first_submitted_qc>November 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2015</results_first_posted>
  <last_update_submitted>November 4, 2015</last_update_submitted>
  <last_update_submitted_qc>November 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meditation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through flyers posted in targeted clinics and clinical referrals at the Minneapolis VA Medical Center.</recruitment_details>
      <pre_assignment_details>Participants completed a 5-hour eligibility and baseline assessment that included a structured clinical interview and self-report measures. Randomization occurred for those meeting study inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Mindfulness-Based Stress Reduction (MBSR)</title>
          <description>Mindfulness-Based Stress Reduction (MBSR): Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Present-Centered Group Therapy (PCGT)</title>
          <description>Present-Centered Group Therapy (PCGT): Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Mindfulness-Based Stress Reduction (MBSR)</title>
          <description>Mindfulness-Based Stress Reduction (MBSR): Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Present-Centered Group Therapy (PCGT)</title>
          <description>Present-Centered Group Therapy (PCGT): Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="10.4"/>
                    <measurement group_id="B2" value="59.4" spread="9.2"/>
                    <measurement group_id="B3" value="58.5" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Service Era</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>OEF/OIF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gulf War</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vietnam War</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime trauma exposure</title>
          <units>No. of events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="3.3"/>
                    <measurement group_id="B2" value="7.5" spread="3.0"/>
                    <measurement group_id="B3" value="7.7" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime trauma exposure event type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Combat exposure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual trauma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical assault</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disaster exposure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious accident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening illness or injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other traumatic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PTSD diagnosis</title>
          <description>Full PTSD criteria defined according to the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV). Subthreshold PTSD defined as endorsement of DSM-IV criterion A1 and at least 1 symptom each from criteria B, C, and D with significant impairment.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Full PTSD criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subthreshold PTSD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbid mood disorder</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Taking psychotropic medication</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total number of psychotherapy mental health visits</title>
          <units>sessions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.2" spread="28.3"/>
                    <measurement group_id="B2" value="14.6" spread="29.2"/>
                    <measurement group_id="B3" value="13.9" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of previous mental health care</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" spread="53.3"/>
                    <measurement group_id="B2" value="63.9" spread="45.2"/>
                    <measurement group_id="B3" value="66.5" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants receiving 8 or more therapy sessions in PTSD or mental health clinics</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PTSD Symptoms on the PTSD Checklist (PCL) at Baseline, During Treatment, After Treatment and at 2-Month Follow-up</title>
        <description>The PCL is a valid and reliable measure of PTSD symptoms. Score range from 17-85; higher scores indicate more severe symptoms. The minimal clinically important difference for self-reported PTSD symptom severity is a reduction of 10 or more points on the PCL.</description>
        <time_frame>Baseline, Weeks 3, 6, 9 and 17</time_frame>
        <population>Intent to treat population (all participants randomized to treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Mindfulness-Based Stress Reduction (MBSR)</title>
            <description>Mindfulness-Based Stress Reduction (MBSR): Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Present-Centered Group Therapy (PCGT)</title>
            <description>Present-Centered Group Therapy (PCGT): Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Symptoms on the PTSD Checklist (PCL) at Baseline, During Treatment, After Treatment and at 2-Month Follow-up</title>
          <description>The PCL is a valid and reliable measure of PTSD symptoms. Score range from 17-85; higher scores indicate more severe symptoms. The minimal clinically important difference for self-reported PTSD symptom severity is a reduction of 10 or more points on the PCL.</description>
          <population>Intent to treat population (all participants randomized to treatment).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline PCL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="60.6" upper_limit="66.7"/>
                    <measurement group_id="O2" value="58.8" lower_limit="55.7" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 PCL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" lower_limit="60.8" upper_limit="67.0"/>
                    <measurement group_id="O2" value="61.7" lower_limit="58.6" upper_limit="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wee 6 PCL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" lower_limit="58.1" upper_limit="64.4"/>
                    <measurement group_id="O2" value="60.7" lower_limit="57.6" upper_limit="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 PCL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7" lower_limit="52.6" upper_limit="58.9"/>
                    <measurement group_id="O2" value="55.8" lower_limit="52.7" upper_limit="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17 PCL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4" lower_limit="51.2" upper_limit="57.6"/>
                    <measurement group_id="O2" value="56.0" lower_limit="52.9" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Improvement in Self-reported PTSD Symptoms as Measured by the PCL</title>
        <description>% of participants with clinically significant improvement in self-reported PTSD symptoms defined as a reduction of 10 points or more on the PCL.</description>
        <time_frame>Weeks 9 and 17</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Mindfulness Based Stress Reduction (MBSR)</title>
            <description>Mindfulness-Based Stress Reduction (MBSR): Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Present Centered Group Therapy (PCGT)</title>
            <description>Present-Centered Group Therapy (PCGT): Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Improvement in Self-reported PTSD Symptoms as Measured by the PCL</title>
          <description>% of participants with clinically significant improvement in self-reported PTSD symptoms defined as a reduction of 10 points or more on the PCL.</description>
          <population>Intent to treat analysis</population>
          <units>percentage clinical responders</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% responders, Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" lower_limit="24" upper_limit="49"/>
                    <measurement group_id="O2" value="22.8" lower_limit="10.9" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% responders, Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" lower_limit="35.1" upper_limit="62.8"/>
                    <measurement group_id="O2" value="28.1" lower_limit="15.5" upper_limit="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSD Symptom Severity on the Clinician Administered PTSD Scale (CAPS) at Baseline, After Treatment, and at 2-Month Follow-up</title>
        <description>The CAPS is a valid and reliable measure of PTSD symptom severity. Score range from 0-136; higher scores indicate more severe symptoms. The minimal clinically important difference for self-reported PTSD symptom severity is a reduction of 10 or more points on the CAPS.</description>
        <time_frame>Baseline, Weeks 9 and 17</time_frame>
        <population>Intent to treat population (all participants randomized to treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Mindfulness-Based Stress Reduction (MBSR)</title>
            <description>Mindfulness-Based Stress Reduction (MBSR): Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Present-Centered Group Therapy (PCGT)</title>
            <description>Present-Centered Group Therapy (PCGT): Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Symptom Severity on the Clinician Administered PTSD Scale (CAPS) at Baseline, After Treatment, and at 2-Month Follow-up</title>
          <description>The CAPS is a valid and reliable measure of PTSD symptom severity. Score range from 0-136; higher scores indicate more severe symptoms. The minimal clinically important difference for self-reported PTSD symptom severity is a reduction of 10 or more points on the CAPS.</description>
          <population>Intent to treat population (all participants randomized to treatment).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline CAPS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" lower_limit="65.0" upper_limit="74.8"/>
                    <measurement group_id="O2" value="62.5" lower_limit="57.6" upper_limit="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 CAPS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" lower_limit="51.0" upper_limit="61.5"/>
                    <measurement group_id="O2" value="51.7" lower_limit="46.5" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17 CAPS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" lower_limit="44.3" upper_limit="55.3"/>
                    <measurement group_id="O2" value="50.6" lower_limit="45.4" upper_limit="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression Symptom Severity on the Patient Health Questionnaire-9 (PHQ-9) at Baseline, After Treatment, and at 2-Month Follow-up</title>
        <description>The PHQ-9 is a valid and reliable measure of depression symptom severity. Score range from 0-27; higher scores indicate more severe symptoms. The minimal clinically important difference for self-reported PTSD symptom severity is a reduction of 5 or more points on the PHQ-9.</description>
        <time_frame>Baseline, Weeks 9 and 17</time_frame>
        <population>Intent to treat population (all participants randomized to treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Mindfulness-Based Stress Reduction (MBSR)</title>
            <description>Mindfulness-Based Stress Reduction (MBSR): Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Present-Centered Group Therapy (PCGT)</title>
            <description>Present-Centered Group Therapy (PCGT): Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.</description>
          </group>
        </group_list>
        <measure>
          <title>Depression Symptom Severity on the Patient Health Questionnaire-9 (PHQ-9) at Baseline, After Treatment, and at 2-Month Follow-up</title>
          <description>The PHQ-9 is a valid and reliable measure of depression symptom severity. Score range from 0-27; higher scores indicate more severe symptoms. The minimal clinically important difference for self-reported PTSD symptom severity is a reduction of 5 or more points on the PHQ-9.</description>
          <population>Intent to treat population (all participants randomized to treatment).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline PHQ-9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="13.9" upper_limit="17.0"/>
                    <measurement group_id="O2" value="14.6" lower_limit="13.1" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 PHQ-9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="12.0" upper_limit="15.1"/>
                    <measurement group_id="O2" value="13.9" lower_limit="12.3" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17 PHQ-9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="11.7" upper_limit="15.0"/>
                    <measurement group_id="O2" value="13.8" lower_limit="12.2" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Improvement in Clinician Administered PTSD Scale (CAPS)</title>
        <description>% of participants with clinically significant improvement in interviewer-rated PTSD symptom severity defined as a reduction of 10 points or more on the CAPS.</description>
        <time_frame>Weeks 9 and 17</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Mindfulness Based Stress Reduction (MBSR)</title>
            <description>Mindfulness-Based Stress Reduction (MBSR): Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Present Centered Group Therapy (PCGT)</title>
            <description>Present-Centered Group Therapy (PCGT): Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Improvement in Clinician Administered PTSD Scale (CAPS)</title>
          <description>% of participants with clinically significant improvement in interviewer-rated PTSD symptom severity defined as a reduction of 10 points or more on the CAPS.</description>
          <population>Intent to treat analysis</population>
          <units>percentage clinical responders</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% responders, Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" lower_limit="49.8" upper_limit="77.1"/>
                    <measurement group_id="O2" value="49.1" lower_limit="36.1" upper_limit="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% responders, Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="52.1" upper_limit="81.2"/>
                    <measurement group_id="O2" value="54.5" lower_limit="41.4" upper_limit="67.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Mindfulness-Based Stress Reduction (MBSR)</title>
          <description>Mindfulness-Based Stress Reduction (MBSR): Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Present-Centered Group Therapy (PCGT)</title>
          <description>Present-Centered Group Therapy (PCGT): Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crushed by falling tree</sub_title>
                <description>Survived with multiple physical injuries</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide Attempt or worsening of symptoms</sub_title>
                <description>Resulted in inpatient hospitalization.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Initial analyses did not account for clustering effects. However, when we re-analyzed data using a multilevel model including a random effect for therapy group, we found that the results were essentially unchanged.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kelvin O. Lim, MD (Principal Investigator)</name_or_title>
      <organization>Minneapolis VA Medical Center</organization>
      <phone>612-467-3323</phone>
      <email>kolim@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

